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Abstract
Background Darunavir is an anti-HIV protease inhibitor repurposed for SARS-CoV-2 treatment.
Objective The aim of this study was to assess the population pharmacokinetics of darunavir in SARS-CoV-2 patients com-
pared with HIV patients.
Methods Two separate models were created by means of a nonlinear mixed-effect approach. The influence of clinical covari-
ates on each basic model was tested and the association of significant covariates with darunavir parameters was assessed at 
multivariate regression and classification and regression tree (CART) analyses. Monte Carlo simulation assessed the influ-
ence of covariates on the darunavir concentration versus time profile.
Results A one-compartment model well-described darunavir concentrations in both groups. In SARS-CoV-2 patients (n = 30), 
interleukin (IL)-6 and body surface area were covariates associated with darunavir oral clearance (CL/F) and volume of 
distribution (Vd), respectively; no covariates were identified in HIV patients (n = 25). Darunavir CL/F was significantly lower 
in SARS-CoV-2 patients compared with HIV patients (4.1 vs. 10.3 L/h; p < 0.001). CART analysis found that an IL-6 level 
of 18 pg/mL may split the SARS-CoV-2 population in patients with low versus high darunavir CL/F (mean ± standard devia-
tion 3.47 ± 1.90 vs. 8.03 ± 3.24 L/h; proportion of reduction in error = 0.46). Median (interquartile range) darunavir CL/F 
was significantly lower in SARS-CoV-2 patients with IL-6 levels ≥ 18 pg/mL than in SARS-CoV-2 patients with IL-6 levels 
< 18 pg/mL or HIV patients (2.78 [2.16–4.47] vs. 7.24 [5.88–10.38] vs. 9.75 [8.45–13.79] L/h, respectively; p < 0.0001). 
Increasing IL-6 levels affected darunavir concentration versus time simulated profiles. We hypothesized that increases in 
IL-6 levels associated with severe SARS-CoV-2 disease may downregulate the cytochrome P450 (CYP) 3A4-mediated 
metabolism of darunavir.
Conclusions This is a proof-of-concept of SARS-CoV-2 disease–drug interactions, and may support the need for optimal 
dose selection of sensitive CYP3A4 substrates in severe SARS-CoV-2 patients.
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s4026 2-020-00933 -8) contains 
supplementary material, which is available to authorized users.
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1 Introduction
The spread of the 2019 novel coronavirus (SARS-CoV-2) 
disease that emerged from China last December has reached 
pandemic proportions and has become a major global health 
concern. According to the WHO reports, as at 30 July 2020 
more than 16.5 million cases and 655,000 deaths have been 
reported worldwide [1]. Since the beginning of the European 
outbreak, Italy has been deeply affected [2] and confirmed 
cases accounted for 1.5% of the WHO global prevalence 
estimate [1].
SARS-CoV-2 may cause illness of increasing severity. 
The earliest report of SARS-CoV-2 from the Chinese Cent-
ers for Disease Control and Prevention noted that among 
72,314 cases, 81% were of a mild nature, with an overall 
 P. G. Cojutti et al.
Key Points 
The anti-HIV protease inhibitor darunavir is one of the 
antiviral drugs repurposed for SARS-CoV-2 treatment. 
We developed and compared population pharmacoki-
netic models of darunavir in SARS-CoV-2 and HIV 
patients.
The population pharmacokinetics of darunavir may differ 
in SARS-CoV-2 patients compared with HIV patients. 
Interleukin (IL)-6 is the most significant clinical covari-
ate affecting the oral clearance of darunavir in patients 
with severe disease by downregulating cytochrome P450 
(CYP) 3A4 activity.
This may represent a proof-of-concept of SARS-CoV-2 
disease–drug interactions, and may support the need for 
optimal dose selection of any sensitive CYP3A4 sub-
strate in SARS-CoV-2 patients with severe disease.
Hospital in the Friuli Venezia Giulia Region were treated 
with darunavir. These patients underwent routine therapeutic 
drug monitoring (TDM) during treatment and we noticed 
that in several cases, plasma concentrations of daruna-
vir were much higher than those usually observed among 
HIV patients treated with the same drug. Since darunavir 
is metabolized by cytochrome P450 (CYP) 3A4 in the liver 
and the gut [7], we hypothesized that SARS-CoV-2 disease 
might have affected CYP3A4 activity.
The aim of this study was to assess the population phar-
macokinetics of darunavir in SARS-CoV-2 patients com-
pared with HIV patients, for identifying any potential covari-
ates that could affect the pharmacokinetics of darunavir in 
SARS-CoV-2 patients.
2  Methods
2.1  Study Design
This was a retrospective, single-center, observational study 
carried out at the Santa Maria della Misericordia University 
Hospital of Udine, Italy, between 15 March and 15 May 
2020. All SARS-CoV-2 patients admitted at the Clinic of 
Infectious Diseases who were treated with darunavir were 
included in this study. The standard formulation of darunavir 
used was DRV/COBI (800/150 mg/day). In the case of an 
in-hospital shortage of DRV/COBI at the time of admis-
sion, the DRV/RTV formulation (800/100 mg/day) was 
used. Each SARS-CoV-2 patient received only one type of 
formulation (either DRV/COBI or DRV/RTV) throughout 
the whole treatment period. HIV patients treated with a 
fixed-drug combination of DRV/COBI (800/150 mg/day), 
emtricitabine (200 mg), and tenofovir (10 mg) [DRV/COBI/
FTC/TAF,  Symtuza®] who underwent TDM of darunavir in 
the same period as the SARS-CoV-2 subjects were included 
as the comparator group. The rationale for considering this 
study design as being reliable for population pharmacoki-
netic modeling is based on the findings of comparative phar-
macokinetic studies between DRV/COBI (800/150 mg/day), 
either as single agents or in a fixed-drug combination, and 
DRV/RTV (800/100 mg/day). The full bioequivalence of 
darunavir was shown, in terms of area under the concen-
tration–time curve (AUC) and peak concentration (Cmax), 
between the two formulations (AUC geometric mean 
ratio range 0.96–1.02; Cmax geometric mean ratio range 
0.97–1.03) [8, 9], even if the trough concentrations (Cmin) 
were approximately 30% lower for DRV/COBI.
All patients routinely underwent TDM of darunavir. 
SARS-CoV-2 patients underwent TDM assessment at least 
48 h after commencing therapy, while HIV patients were 
receiving chronic and stable treatment. In both groups, each 
patient provided two blood samples—the first just before a 
case fatality rate of 2.3%, whereas 5% presented with res-
piratory failure, septic shock, and multiorgan dysfunction, 
resulting in a fatality rate of 50% of such cases [1]. Con-
sequently, a three-stage classification system has recently 
been proposed for characterizing the increasing severity of 
illness with distinct clinical findings, response to therapy, 
and clinical outcome: stage I (mild), early infection; stage II 
(moderate), pulmonary involvement (IIa) without and (IIb) 
with hypoxia (defined as  PaO2/FiO2 ≤ 300 mmHg); and stage 
III (severe), systemic hyperinflammation [3]. Stages I and IIa 
have been mainly associated with viral proliferation and less 
severe disease, while stages IIb and III have been associated 
with overwhelming inflammatory response and cytokine 
burden, which may precipitate in multiple organ failure, with 
unfavorable clinical outcome and death [4, 5]. Although no 
approved drug treatment currently exists for SARS-CoV-2 
disease, hundreds of clinical trials are currently ongoing 
with the intention of finding an effective treatment, looking 
at the available therapeutic armamentarium [6]. These trials 
include various drugs with antiviral activity, immunomodu-
latory activity, or both [6].
The anti-HIV protease inhibitor darunavir is one of the 
antiviral drugs repurposed for SARS-CoV-2 treatment, and 
is currently under investigation in six different clinical tri-
als registered at ClinicalTrials.gov [6]. Three trials included 
darunavir in the darunavir/cobicistat (DRV/COBI) formula-
tion, and the remaining three trials included darunavir/rito-
navir (DRV/RTV) [6]. During the overwhelming outbreak 
of SARS-CoV-2 disease that occurred in March/April 2020 
in Italy, some SARS-CoV-2 patients who were hospitalized 
at the Clinic of Infectious Diseases of the Udine University 
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daily dose for assessing Cmin, and the second 2 h after oral 
drug administration for assessing Cmax. After blood centrifu-
gation and plasma separation, concentrations of darunavir 
were measured in plasma using liquid chromatography-tan-
dem mass spectrometry (LC–MS/MS) (Shimadzu LC-20 
AB Sciex 3200 Qtrap) by means of a commercially avail-
able method  (MassTox® TDM Series A Anti-HIV drugs, 
Catalogue No. 92924; Chromsystems GmbH, Munich, Ger-
many). The lower limit of quantification was 6 ng/mL [10].
This study was approved by the Regional Ethics Com-
mittee of Friuli Venezia Giulia Region, Italy. In light of the 
retrospective nature of the study, written informed consent 
was waived, according to the institutional policies for studies 
with a retrospective design.
The following demographic and clinical data were retrieved 
from patient records: age, sex, weight, height, diagnosis, 
comorbidities, coadministered drugs, and drug-related adverse 
events (if any). The following laboratory parameters were col-
lected on the day of the TDM assessment: serum creatinine, 
serum albumin, alanine aminotransferase (ALT), aspartate 
aminotransferase (AST), total bilirubin, γ-glutamyltransferase 
(γ-GT), and interleukin (IL)-6. IL-6 was assessed as a bio-
marker of acute inflammatory progression in SARS-CoV-2 
patients [11] and as a biomarker of chronic inflammatory state 
in HIV patients [12]. The severity of SARS-CoV-2 disease 
was classified according to the three-stage classification sys-
tem proposed by Siddiqi and Mehra [3].
2.2  Population Pharmacokinetic Modeling
Two comparative population pharmacokinetic models were 
created, one for SARS-CoV-2 patients and the other for HIV 
patients. Darunavir plasma concentrations were analyzed by 
means of nonlinear mixed-effects modeling using the sto-
chastic approximation expectation maximization (SAEM) 
algorithm implemented within the Monolix software (ver-
sion 2019R1; Lixofit, Antony, France). The timepoints of 
darunavir TDM assessment were exactly those related to 
the start of treatment in SARS-CoV-2. Conversely, six fixed 
drug doses were virtually added before timepoints of daruna-
vir TDM assessment in HIV patients for simulating steady-
state conditions, since those patients had been under chronic 
treatment for months/years.
A basic model was developed by comparing one- and 
two-compartment models with first-order oral absorption 
and elimination. All individual parameters were considered 
to be log-normally distributed. Exponential random effects 
were assumed to describe between-subject variability. Cor-
relations between random effects were tested in the vari-
ance–covariance matrix, and implemented into the structural 
model accordingly. Several error models (constant, propor-
tional, or combined) were tested for describing the residual 
variability. The most appropriate model was selected on the 
basis of the following criteria: minimum value of both the 
objective function value (OFV) and the Bayesian informa-
tion criteria (BIC), adequacy of the goodness-of-fit plots, 
and minimum value of the relative standard error (RSE) of 
the estimated pharmacokinetic parameters.
The potential influence of covariates was tested separately 
on each basic model of the darunavir pharmacokinetics. The 
tested covariates were age, sex, weight, height, body surface 
area (BSA), serum albumin, serum creatinine, total bilirubin, 
ALT, AST, γ-GT, IL-6, and stage of SARS-CoV-2 disease 
according to the three-stage classification system of Siddiqi 
and Mehra [3]. The parameter–covariate relationship was 
modeled as additive or proportional shifts from the reference 
category for binary covariates, and the effect of continu-
ous covariates was modeled using a power function. The 
covariate model was built using a stepwise procedure with 
forward inclusion and backward elimination. A covariate 
was retained in each of the two final models if the OFV 
decreased by at least 3.84 and both the BIC and interpatient 
variability of the fixed-effect parameters were decreased 
compared with the corresponding basic model.
2.3  Model Evaluation
Evaluation of each final model was based on the following 
goodness-of-fit plots: observation versus individual and pop-
ulation predictions, usual residual-based plots (individual-
weighted residuals and population-weighted residuals), and 
visual predicted check (VPC) plot. The VPC plot depicts 
the time course of the 10th, 50th, and 90th percentiles of 
observed data and the corresponding 90% prediction inter-
vals calculated from 500 Monte Carlo samples. Model per-
formance was also assessed by means of the normalized 
prediction distribution error (NPDE). The 99% confidence 
interval of each parameter was simulated in each final model 
by performing 1000 nonparametric bootstraps with resam-
pling in the Rsmlx package of R (R speaks Monolix).
2.4  Monte Carlo Simulation of the Effect 
of Covariates
The influence of a covariate eventually retained in the two 
final models on the plasma concentration versus time profile 
of darunavir was assessed by means of the Mlxplore package 
of Monolix. Overall, 1000 Monte Carlo simulations were 
conducted in each scenario using a 10-day standard daily 
dose of darunavir 800 mg (simulating either DRV/COBI 
800/150 mg or DRV/RTV 800/100 mg).
2.5  Statistical Analysis
The Kolmogorov–Smirnov test was used for assess-
ing normal or non-normal distribution of patients’ data. 
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Consequently, descriptive statistical data were presented as 
mean ± standard deviation (SD) or median and 25th–75th 
percentiles (interquartile range [IQR]). Categorical vari-
ables were compared using the Chi square test with Yates’s 
correction, or Fisher’s exact test, as appropriate, while con-
tinuous variables were compared using the Student’s t test 
or Mann–Whitney test, as appropriate. The strength of a 
trend between two variables was expressed by means of the 
Pearson correlation coefficient or Spearman’s rank correla-
tion coefficient, as appropriate. Univariate and multivari-
ate linear regression analysis was conducted for assessing 
the potential association between patient covariates and 
darunavir pharmacokinetic parameters. A p-value ≤ 0.05 
was required for statistical significance. Classification and 
regression tree (CART) analysis was carried out for assess-
ing whether a covariate threshold could be associated with 
darunavir pharmacokinetic parameters. The proportion of 
reduction in error (PRE) was used as goodness-of-fit sta-
tistics for CART analysis, and the Kruskal–Wallis test was 
used to compare continuous data among groups. Bonferroni 
correction for multiple comparison was applied as appropri-
ate. All statistical analysis and plotting was performed using 
R version 3.4.4 (The R Foundation for Statistical Comput-
ing, Vienna, Austria).
3  Results
Thirty SARS-CoV-2 patients and 25 HIV patients were 
included in this study. The demographic and clinical char-
acteristics of the two groups are summarized in Table 1. The 
two groups were similar in terms of sex and distribution of 
body size metric characteristics. Median age was higher in 
SARS-CoV-2 patients than in HIV patients (63 vs. 47 years; 
p < 0.001). Levels of ALT, AST, bilirubin, and γ-GT were 
significantly higher in SARS-CoV-2 patients compared 
with HIV patients, and IL-6 levels were highly signifi-
cantly higher in SARS-CoV-2 patients than in HIV patients 
(median 31.0 [IQR 10–114.75] vs. 2.0 [IQR 2.0–2.75] pg/
mL; p < 0.001).
The clinical data of each of the SARS-CoV-2 and HIV 
patients are summarized in Electronic Supplementary 
Tables S1 and S2, respectively. Among the SARS-CoV-2 
patients (Electronic Supplementary Table S1), 22 of 30 
patients (73.3%) were treated with DRV/COBI, whereas 8 
of 30 (26.7%) received DRV/RTV. Most of the SARS-CoV-2 
patients were affected by severe disease (three at stage I, 
eight at stage IIa, ten at stage IIb, and nine at stage III). 
Seven patients had no comorbidities (7/30, 23.3%), nine 
had one comorbidity (9/30, 30,0%) and the remaining 14 
had two or more comorbidities (14/30, 46.7%). All patients 
were co-treated with other drugs (the range of coadminis-
tered drugs was 1–8). Only one of the coadministered drugs 
was a potential perpetrator of CYP3A4-mediated drug–drug 
interactions (amiodarone was started in one patient 2 days 
before DRV/COBI).
Among the HIV patients (Electronic Supplementary 
Table  S2), all were treated with DRV/COBI/FTC/TAF 
(25/25, 100%). Ten patients had no comorbidities (10/25, 
40.0%), five had one comorbidity (5/25, 20,0%), and the 
remaining ten patients had two or more comorbidities 
(10/25, 40.0%). Twenty of 25 patients (20/25, 80%) were co-
treated with other drugs (the range of coadministered drugs 
was 1–8). None of the coadministered drugs was a potential 
perpetrator of CYP3A4-mediated drug–drug interaction.
3.1  Comparative Population Pharmacokinetic 
Analysis of Darunavir
Both the Cmin and Cmax of darunavir were significantly higher 
in SARS-CoV-2 patients than HIV patients (median Cmin 
4960.2 ng/mL [IQR 2015.0–7951.2] vs. 1010.0 ng/mL [IQR 
550.0–2112.0], p < 0.001; median Cmax 9476.2 ng/mL [IQR 
7220.5–14835.4] vs. 6320.0 ng/mL [IQR 3888.3–7747.5], 
p < 0.001) [Fig. 1].
In both patient populations, darunavir pharmacokinetic 
concentrations were best described by a one-compartment 
model (OFV/BIC for one- vs. two- compartment models: 
298.93 vs. 321.74 and 299.59 vs. 337.01, respectively, in 
SARS-CoV-2 patients; 181.67 vs. 214.42 and 182.55 vs. 
217.96, respectively, in HIV patients). Population pharma-
cokinetic parameter estimates are reported in Table 2. In the 
SARS-CoV-2 final pharmacokinetic model, two covariates 
were significantly associated with darunavir pharmacoki-
netic parameters: IL-6 with darunavir oral clearance (CL/F), 
and BSA with volume of distribution (Vd). On the contrary, 
no covariate was found to be significantly associated with 
any of the darunavir pharmacokinetic parameters in the HIV 
final pharmacokinetic model. Either fixed-effect or random-
effect estimates were accurate in both models (except for 
interindividual variability in Vd). All of the pharmacokinetic 
parameter estimates were significantly different between the 
two groups. Noteworthy, darunavir CL/F was approximately 
2.5-fold lower (4.1 vs. 10.3 L/h; p < 0.001) and median daru-
navir exposure was more or less 2.1-fold higher (AUCs of 
161,387.0 vs. 75,727.0 ng·h/mL; p < 0.001) in SARS-CoV-2 
patients compared with HIV patients.
Linear regression of the observed versus model-pre-
dicted individual concentrations showed a very good fit, for 
both SARS-CoV-2 patients (R2 = 0.92) and HIV patients 
(R2 = 0.98) [Electronic Supplementary Fig. S1]. The VPC 
plot showed a consistent distribution between the observed 
and predicted concentrations in both populations (Fig. 2). 
The residuals were normally distributed (p = 0.344 and 
p = 0.159 in the Shapiro–Wilk test for SARS-CoV-2 and HIV 
patients, respectively), and were symmetric at approximately 
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zero (p = 0.156 and p = 0.219 in the symmetry test for SARS-
CoV-2 and HIV patients, respectively).
3.2  The Prominent Role of Interleukin‑6 
on Darunavir Pharmacokinetics in SARS‑CoV‑2 
Patients
IL-6 showed a trend toward a significant relationship with 
the three-stage classification system of SARS-CoV-2 dis-
ease severity (Spearman ρ = 0.34, p = 0.07) and was the only 
clinical variable highly significantly associated with daru-
navir CL/F at multivariate regression analysis (p < 0.001) 
[Table 3]. The multivariate model accounted for approxi-
mately 50% of the darunavir CL/F variability (R2 = 0.494; 
p < 0.001). CART analysis (Electronic Supplementary 
Fig. S2) found that an IL-6 level of 18 pg/mL may ade-
quately split the SARS-CoV-2 population in patients with 
low versus high darunavir CL/F (mean ± SD 3.47 ± 1.90 vs. 
8.03 ± 3.24 L/h; PRE = 0.46).
The distribution of darunavir CL/F in SARS-CoV-2 
patients with IL-6 levels ≥ 18 pg/mL compared with those 
with IL-6 levels < 18 pg/mL, and HIV patients, are depicted 
in Fig. 3. Median darunavir CL/F was significantly lower in 
SARS-CoV-2 patients with IL-6 levels ≥ 18 pg/mL than in 
those with IL-6 levels < 18 pg/mL, or HIV patients (2.78 
[IQR 2.16–4.47] vs. 7.24 [IQR 5.88–10.38] vs. 9.75 [IQR 
8.45–13.79] L/h, respectively; p < 0.0001). Conversely, 
darunavir CL/F in SARS-CoV-2 patients with IL-6 lev-
els < 18 pg/mL was not significantly different from that 
of HIV patients (7.24 [IQR 5.88–10.38] vs. 9.75 [IQR 
8.45–13.79] L/h; p = 0.126].
Figure 4 depicts the simulated median plasma concentra-
tion versus time profiles achievable with a 10-day course 
of darunavir in HIV and SARS-CoV-2 patients with three 
different increasing levels of IL-6. Median darunavir Cmin 
and Cmax estimates at steady-state were 826 (IQR 239–1824) 
and 5.425 (IQR 4.229–6.921) ng/mL in HIV patients; 1460 
(IQR 550–2920) and 7.560 (IQR 6.147–9.242) ng/mL in 
SARS-CoV-2 patients with IL-6 levels of 1 pg/mL; 7020 
(IQR 4090–11,380) and 13.418 (IQR 10.468–17.911) ng/
mL in patients with IL-6 levels of 100 pg/mL; and 14,140 
(IQR 9100–21,230) and 20.729 (IQR 15.541–27.778) ng/
mL in patients with IL-6 levels of 1000 pg/mL.
Table 1  Demographics and clinical characteristics of the study groups
Data are expressed as median (interquartile range) for continuous variables and n (%) for dichotomous variables
ADRs adverse drug reactions, BSA body surface area, TDM therapeutic drug monitoring
SARS-CoV-2-infected patients HIV-infected patients p-Value
Patient demographics
 No. of patients 30 25
 Sex (male/female) 18/12 (60/40) 18/7 (72/28) 0.404
 Age, years 63 (55–70.5) 47 (40–51) < 0.001
 Body weight, kg 75.0 (69.25–81.50) 75.0 (66.0–84.0) 0.904
 BSA,  m2 1.86 (1.77–1.96) 1.86 (1.75–2.02) 0.689
Laboratory parameters
 Serum creatinine, mg/dL 0.86 (0.78–1.05) 0.93 (0.84–1.07) 0.424
 Bilirubin, mg/dL 0.46 (0.38–0.62) 0.35 (0.23–0.48) 0.026
 Alanine aminotransferase, UI/L 40.0 (21.0–71.0) 20.0 (17.0–29.0) 0.002
 Aspartate aminotransferase, UI/L 36.0 (24.0–55.0) 20.0 (17.0–22.0) 0.004
 γ-Glutamyltransferase, UI/L 53.5 (35.5–125.2) 22.0 (12.0–35.0) 0.035
 Interleukin-6, pg/mL 31.0 (10–114.75) 2.0 (2.0–2.75) < 0.001
Post-starting treatment time of TDM, days 3.0 (2.0–5.0) – –
Comedications
 No. of drugs per patient 3.5 (2.0–5.75) 4.0 (3.0–6.0) 0.151
ADRs
 No. of patients with ADRs 8 (26.7) 1 (4.0) 0.031
 Type of ADRs
  Abdominal pain/diarrhea 3 1 0.617
  QT prolongation 2 0 –
  Asthenia 1 0 –
  Tonic–clonic seizure 1 0 –
  Rash 1 0 –
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4  Discussion
The present study investigated the population pharmacoki-
netics of darunavir in SARS-CoV-2 patients compared with 
HIV patients. The clinical covariates that may alter daru-
navir pharmacokinetics in SARS-CoV-2 patients were also 
assessed, and conceptualization of a disease-drug interaction 
was formulated.
Fig. 1  Box-and-whisker plots 
(5th and 95th percentiles) of 
darunavir trough and peak 
plasma concentrations in SARS-
CoV-2 patients (blue, n = 30) 
and HIV patients (orange, 
n = 25)
Table 2  Summary of population pharmacokinetic parameters of darunavir in SARS-CoV-2 patients compared with HIV patients
Results are expressed as estimated parameter value
βBSA-Vd exponentiation coefficient of BSA on Vd, βIL6-CL/F exponentiation coefficient of IL-6 on CL/F, CI confidence interval, CL/F oral clear-
ance, ka first-order absorption rate constant, %RSE percentage relative standard error, Vd volume of distribution of the central compartment
SARS-CoV-2 patients HIV patients p-Value
Value (RSE%) Median (99% CI) of bootstrap Value (RSE%) Median (99% CI) of bootstrap
Fixed effects
 ka  (h−1) 0.74 (30.6) 0.58 (0.55–0.75) 0.58 (36.6) 0.59 (0.55–0.66) 0.047
 CL/F (L/h) 4.10 (10.1) 3.98 (3.93–4.11) 10.3 (10.4) 10.4 (10.2–10.6) < 0.001
 βIL6-CL/F − 0.23 (24.9) − 0.22 (− 0.23 to − 0.21) – – –
 Vd (L) 88.41 (7.8) 77.81 (76.13–89.17) 96.9 (11.5) 99.4 (96.7–102.0) 0.002
 βBSA-Vd 1.44 (35.9) 1.43 (1.31–1.71) – – –
Between-subject variability
 ω ka (%) 0.82 (28.3) 0.97 (0.93–1.10) 1.14 (24.6) 1.19 (1.12–1.25) 0.033
 ω CL (%) 0.53 (15.2) 0.53 (0.51–0.53) 0.44 (19.5) 0.46 (0.44–0.48) 0.047
 ω Vd (%) 0.15 (41.0) 0.13 (0.11–0.16) 0.13 (61.5) 0.18 (0.12–0.20) < 0.001
Residual variability
b (proportional) 0.09 (22.3) 0.08 (0.07–0.09) 0.155 (64.2) 0.17 (0.16–0.19) –
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The population pharmacokinetic models that we devel-
oped showed darunavir CL/F was highly significantly lower 
in SARS-CoV-2 patients than in HIV patients, and that IL-6 
was the only clinical covariate that significantly affected 
darunavir CL/F in SARS-CoV-2 patients.
The population pharmacokinetic model that we developed 
in HIV patients receiving DRV/COBI/FTC/TAF was reliable 
for comparison with SARS-CoV-2 patients as it provided 
darunavir CL/F estimates (10.3  L/h) similar to those 
observed in two recent population pharmacokinetic analy-
sis carried out in HIV patients receiving DRV/RTV. In a 
recent multicenter, retrospective study assessing the popula-
tion pharmacokinetics of darunavir among 368 HIV patients 
treated with DRV/RTV (either in a 800/100 mg once-daily 
formulation [n = 306] or a 600/100 mg twice-daily formula-
tion [n = 62]) darunavir CL/F was 9.47 L/h [13], and was 
Fig. 2  Prediction-corrected visual predictive check for the popula-
tion pharmacokinetic models developed in SARS-CoV-2 and HIV 
patients. The lines represent the median and the 10th and 90th per-
centiles for the observed data. The shaded areas are the prediction 
interval for the median (red central area) and for the 10th and 90th 
percentiles (light blue lower and upper areas)
Table 3  Univariate and multivariate analysis of variables potentially associated with darunavir oral clearance in SARS-CoV-2-infected patients 
(n = 30)
Results are expressed as slope (confidence interval). Statistical analysis by linear regression on log-transformed independent variables (Y = 
β0+β1logX + ε). Adjusted R2: 0.494
Variables significantly associated with darunavir oral clearance at multivariate analysis are in bold
ALT alanine aminotransferase, AST aspartate aminotransferase, BSA body surface area, γ-GT γ-glutamyltransferase, IL interleukin
a Classified according to the work of Siddiqi and Mehra [3]
Variables Univariate analysis Multivariate analysis
Unstandardized β-coefficient p-Value Unstandardized β-coefficient p-Value
Age, years − 4.793 (− 19.078 to 9.492) 0.498
Body weight, kg 8.045 (− 5.106 to 21.196) 0.221
BSA,  m2 9.237 (− 16.421 to 34.895) 0.467
Stage of SARS-CoV-2  progressiona − 6.330 (− 15.299 to 2.640) 0.159 − 0.668 (− 7.898 to 6.561) 0.851
Serum creatinine, mg/dL − 0.721 (− 13.672 to 12.230) 0.910
Total bilirubin, mg/dL 0.005 (− 6.673 to 6.684) 0.999
ALT, UI/L 0.754 (− 2.892 to 4.400) 0.674
AST, UI/L 1.717 (− 2.805 to 6.238) 0.442
γ-GT, UI/L 0.549 (− 2.584 to 3.681) 0.721
Serum albumin, g/dL − 1.437 (− 8.204 to 5.330) 0.663
IL-6, pg/mL − 2.464 (− 3.783 to − 1.145) 0.001 − 2.513 (− 3.795 to 1.232) < 0.001
Hydroxychloroquine 0.513 (− 3.577 to 4.603) 0.799
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even higher (14.6 L/h) in another population pharmacoki-
netic study carried out using data from 716 treatment-naïve 
patients enrolled in a phase III comparative trial of DRT/
RTV 800/100 mg once daily combined with raltegravir in 
one arm or FTC/TAF in the other arm [14].
To our knowledge, this is the first study assessing daruna-
vir population pharmacokinetics in SARS-CoV-2 patients. 
We found that darunavir CL/F was approximately 2.5-fold 
lower in SARS-CoV-2 patients than in HIV patients, and 
that IL-6 was the only clinical covariate that significantly 
affected darunavir CL/F. Darunavir is metabolized by 
CYP3A4 in the liver and gut [7]. IL-6 is one of the most 
important proinflammatory cytokines regulating acute-phase 
protein synthesis in inflammation [15]. Previous studies 
showed that IL-6 increases associated with infection or 
other disease states may downregulate CYP3A4-mediated 
activity [16–19]. Noteworthy, IL-6 burden was shown to 
play a pivotal role in causing systemic hyperinflamma-
tion associated with severe disease states in SARS-CoV-2 
patients [20]. Recent evidence from different groups showed 
a twofold higher lopinavir Cmin in SARS-CoV-2 patients [7, 
21, 22]. Consequently, some observational studies showed 
the IL-6 receptor antagonist tocilizumab may be helpful in 
reducing the fatality rate among patients with severe SARS-
CoV-2 [20, 23, 24]; a prospective, randomized clinical trial 
with tocilizumab has also been designed [25]. Most of our 
patients had severe SARS-CoV-2 disease (overall, 63.3% 
were classified as stage IIb and III) [3], and the severity of 
Fig. 3  Scatter plot of the dis-
tribution of darunavir CL/F in 
SARS-CoV-2 patients with IL-6 
levels < 18 pg/mL (light blue, 
n = 10), SARS-CoV-2 patients 
with IL-6 levels ≥ 18 pg/
mL (purple, n = 20), and HIV 
patients (orange, n = 25). CL/F 
oral clearance, IL interleukin
Fig. 4  Simulated median 
concentration–time profiles 
of darunavir with a daily dose 
of 800 mg in HIV patients 
(orange) and SARS-CoV-2 
patients with IL-6 levels of 
1 pg/mL (light blue), 100 pg/
mL (purple), and 1000 pg/mL 
(blue). Gray shadings around 
simulated profiles display the 
25th–75th percentiles of con-
centrations. IL interleukin
PopPk of Darunavir in SARS-CoV-2
SARS-CoV-2 disease was found to be almost significantly 
correlated with IL-6 levels.
CART analysis revealed that an IL-6 level ≥ 18 pg/mL 
allowed identifying the SARS-CoV-2 patients who had 
darunavir CL/F most significantly impaired. Conversely, 
darunavir CL/F in SARS-CoV-2 patients with IL-6 levels 
below this threshold was almost normal and was similar to 
that of HIV patients. Interestingly, a physiologically based 
pharmacokinetic model assessing the impact of IL-6 on 
sensitive CYP3A4 substrates in virtual rheumatoid arthri-
tis patients may corroborate our hypothesis. In that study, 
it was estimated that the percentage increase of CYP3A4 
victim drug AUC 24 in the presence of IL-6 was 20–50% for 
simvastatin at IL-6 concentrations of 50 pg/mL, and 30% 
for cyclosporine at IL-6 concentrations of 100 pg/mL [26].
Monte Carlo simulations confirmed that the plasma 
concentration–time profiles of darunavir achievable with 
a 10-day course of darunavir may be highly influenced by 
IL-6 levels in SARS-CoV-2 patients. This may represent 
a proof-of-concept of SARS-CoV-2 disease–drug interac-
tions, and may support the need for optimal dose selection 
for darunavir, as well as other sensitive CYP3A4 substrates. 
The findings could claim dosing adjustments of darunavir 
in SARS-CoV-2 patients according to their IL-6 concentra-
tions. However, it should not be overlooked that recent stud-
ies have shown that the probably of in vivo concentrations 
of HIV protease inhibitors are insufficient to inhibit SARS-
CoV-2 [11, 27]. Consequently, it might be hypothesized 
that the higher exposure observed in the presence of high 
IL-6 levels could be more clinically helpful in inhibiting 
SARS-CoV-2.
Prospective studies are urgently needed for promoting 
effective and well tolerated drug treatments with sensitive 
CYP3A4 substrates in severe SARS-CoV-2 patients with 
high IL-6 levels associated with stage IIb and III disease, in 
agreement with what has already been suggested in a recent 
viewpoint claiming for action [28].
We recognize that this study has some limitations. Its 
retrospective nature, the heterogeneity of the different types 
of darunavir formulations, and the small sample size of both 
groups must be acknowledged. Although we recognize that 
a unique population pharmacokinetic model could have 
been managed, we preferred to create two separate mod-
els because we believed that knowing the pharmacokinetic 
parameter estimates within each single population would 
have been interesting. The potential influence of CYP3A4-
mediated drug–drug interactions, OATP1A2 transporter-
mediated hydroxychloroquine interaction, and/or higher 
levels of AST/ALT on darunavir CL/F, as supposed by other 
authors [7], could not be completely ruled out; however, it 
is very unlikely that these factors might have had a major 
role. Only one of our patients was treated with a known 
perpetrator of CYP3A4, and neither hydroxychloroquine 
nor ALT/AST were significantly associated with darunavir 
CL/F at the regression analysis. Conversely, the reliability 
of the parameter estimates in both population pharmacoki-
netic models, and the robust significance of IL-6 as a clinical 
covariate of darunavir CL/F in SARS-CoV-2 patients, are 
valuable points of strength.
5  Conclusion
Our findings showed that darunavir CL/F may be signifi-
cantly impaired in SARS-CoV-2 patients, and that IL-6 
burden may be the clinical covariate that most significantly 
affects darunavir CL/F in patients with severe disease. Fur-
ther prospective studies on larger SARS-CoV-2 populations 
are warranted to confirm our findings. A call for the appro-
priate application of clinical pharmacological principles in 
the search for well tolerated and efficacious SARS-CoV-2 
treatments is urgently needed [29].
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